Lifesci Capital Has Pessimistic View of PVLA FY2026 Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at Lifesci Capital lowered their FY2026 earnings per share estimates for Palvella Therapeutics in a research report issued to clients and investors on Monday, December 15th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($4.72) per share for the year, down from their previous forecast of ($4.17). The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

Several other research firms also recently commented on PVLA. Oppenheimer reaffirmed an “outperform” rating and issued a $200.00 price objective on shares of Palvella Therapeutics in a report on Monday. TD Cowen raised their price target on Palvella Therapeutics from $97.00 to $133.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday. HC Wainwright set a $200.00 price objective on Palvella Therapeutics and gave the stock a “buy” rating in a report on Monday. Finally, Chardan Capital raised their target price on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $155.60.

Palvella Therapeutics Stock Down 5.0%

PVLA opened at $92.01 on Thursday. The firm has a 50-day moving average price of $84.68 and a 200-day moving average price of $56.38. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $112.00. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -34.98 and a beta of -0.20.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $86.23, for a total transaction of $370,961.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. bought a new position in shares of Palvella Therapeutics in the 3rd quarter worth $36,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at $37,000. AlphaQuest LLC bought a new stake in shares of Palvella Therapeutics during the 3rd quarter worth $164,000. Finally, JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.